Analyzing Check-Cap (NASDAQ:MBAI) and Profusa (NASDAQ:PFSA)

Check-Cap (NASDAQ:MBAI) and Profusa (NASDAQ:PFSA) are both small-cap manufacturing companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, dividends, analyst recommendations, valuation, profitability and earnings.

Earnings & Valuation

This table compares Check-Cap and Profusa”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Check-Cap	N/A	N/A	$4.14 million	($2.77)	-0.50
Profusa	$100,000.00	10.45	-$35.82 million	($169.72)	0.00

Check-Cap has higher earnings, but lower revenue than Profusa. Check-Cap is trading at a lower price-to-earnings ratio than Profusa, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

1.1% of Check-Cap shares are owned by institutional investors. Comparatively, 9.8% of Profusa shares are owned by institutional investors. 0.5% of Check-Cap shares are owned by insiders. Comparatively, 0.8% of Profusa shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Check-Cap and Profusa, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Check-Cap	1	0	0	0	1.00
Profusa	1	0	0	0	1.00

Risk & Volatility

Check-Cap has a beta of 0.59, indicating that its share price is 41% less volatile than the S&P 500. Comparatively, Profusa has a beta of 0.35, indicating that its share price is 65% less volatile than the S&P 500.

Profitability

This table compares Check-Cap and Profusa’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Check-Cap	N/A	N/A	N/A
Profusa	N/A	N/A	-1,348.07%

About Check-Cap

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient’s back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation. The company was incorporated in 2004 and is based in Isfiya, Israel.

About Profusa

NorthView Acquisition Corporation does not have significant operations. The company intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It also intends to focus its search on businesses that are focused on healthcare sector. The company was incorporated in 2021 and is based in New York, New York. NorthView Acquisition Corporation is a subsidiary of NorthView Sponsor I, LLC.